(Q33862569)

29 July 2017

Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder (English)

1 reference

generalized anxiety disorder

29 July 2017

1 reference

Goddard AW

1

1 reference

29 July 2017

Woods SW

2

1 reference

29 July 2017

Money R

3

1 reference

29 July 2017

Pande AC

4

1 reference

29 July 2017

Charney DS

5

1 reference

29 July 2017

Goodman WK

6

1 reference

29 July 2017

Heninger GR

7

1 reference

29 July 2017

Price LH

8

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

29 July 2017

1 reference

29 July 2017

85

1 reference

29 July 2017

225-240

1 reference

29 July 2017

3

1 reference

Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Comorbidity of anxiety, phobia, compulsion and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

PD135158, a CCK-B antagonist, reduces "state," but not "trait" anxiety in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

mCPP-induced anxiety in the light-dark box in rats--a new method for screening anxiolytic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Pharmacology of a cholecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The cholecystokinin hypothesis of anxiety and panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Effect of CI-988, a cholecystokinin-B receptor antagonist, on lactate-induced panic.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Biological actions of cholecystokinin

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Differential profile of the CCKB receptor antagonist CI-988 and diazepam in the four-plate test.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Cholecystokinin enhances the acoustic startle response in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Comorbidity of anxiety disorders in a multicenter anxiety study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Cholecystokinin receptors and animal models of anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The CCKB antagonist, L-365,260, attenuates fear-potentiated startle.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

m-Chlorophenylpiperazine as a probe of serotonin function

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Behavioral indications for serotonin receptor hypersensitivity in panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Generalized anxiety disorder in women. A population-based twin study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The 5-HT3 receptor is present in different subpopulations of GABAergic neurons in the rat telencephalon.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Inhibition by 5-HT3 receptor antagonists of release of cholecystokinin-like immunoreactivity from the frontal cortex of freely moving rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Effects of cholecystokinin tetrapeptide and sulfated cholecystokinin octapeptide in rat models of anxiety.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

CCK antagonists: pharmacology and therapeutic interest.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

DSM-III-R generalized anxiety disorder in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-1781%2899%2900015-3

7 January 2021

10.1016/S0165-1781(99)00015-3

Identifiers

DOI

1 reference

29 July 2017

1 reference